Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments.

Meeting to be held in Chicago on April 8 and in San Francisco on April 9 hosted by Oppenheimer. Don't Miss Our End of Quarter Offers: Discover ...

Carlsbad’s Ionis Pharmaceuticals struck a deal worth up to $940 million with Japan-based Ono Pharmaceutical for its medicine ...

In a report released yesterday, Yanan Zhu from Wells Fargo maintained a Buy rating on Ionis Pharmaceuticals (IONS – Research Report), with a ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $55.0, with a high ...